Sr. Scientist, Biology

Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radio conjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes but is not limited to: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial;

FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radio conjugate currently in a Phase 1 trial. Fusion has multiple other pipeline programs that will soon be entering into early FIH trials. In addition, Fusion is pursuing combination programs between RCs and other therapeutic modalities including DNA Damage Response Inhibitors (DDRis) and immune‑oncology agents.

To support execution for these programs, Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state‑of‑the‑art radio conjugate manufacturing facility to meet supply demand for our growing pipeline of RCs.

• Independent technical lead for radio conjugate (RC) research programs in oncology, driving strategy and execution from concept to decision points
  • Apply creative thinking and scientific expertise to understand RC biology such as mechanisms of action, determinants of drug sensitivity and resistance, and rational combination strategies
  • Collaborate closely with cross‑functional internal teams and external partners by setting clear objectives, delivering robust data packages, and communicating results to agreed timelines
  • Present program updates and scientific results at internal governance meetings, project team forums, and external scientific conferences

• Ph.D. in a cancer of radiation biology (or closely related field) with 3+ years of relevant work experience
• Strong knowledge of cancer and/or radiation biology, with a demonstrated commitment to continued learning
• Expertise in cancer cell culture, development & technical validation of fit‑for‑purpose in vitro bioassays, and combination drug testing
• Proficiency with molecular and histology assays, including cytotoxicity assays, receptor binding and internalization, flow cytometry, ELISA, Western blotting and IHC
• Experience designing and interpreting efficacy studies in mouse cancer model is an asset
• Proven ability to thrive in a fast paced, evolving research environment with strong problem solving and prioritization skills
• Excellent verbal and written communication, with a track record of clear data presentation and scientific storytelling
• Experience working in multidisciplinary, collaborative teams and communicating effectively with colleagues at all levels
• Ability to partner and manage external CROs is an asset
• Experience with safe handling of radioactive and biohazardous materials is an asset

Fusion Pharmaceuticals is an equal opportunity employer that is committed to inclusive, barrier‑free recruitment and selection processes, if contacted for an interview, please advise Human Resources if you require accommodation.

All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran

Annual base salary for this position ranges from $ to $. Fusion Pharmaceuticals, a member of Astra Zeneca PLC, is committed to providing fair and equitable compensation opportunities to all colleagues. Our compensation policies and practices have been designed to allow colleagues to progress through the salary range over time as they progress in their role. The range provided in this posting represents an offer pay range used in a majority of situations.

The base pay offered will vary depending on multiple individualized factors, including the candidate's skills and experience, job‑related knowledge, and other specific business and organizational needs. In some cases, offers outside the range may also be considered to…